Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Parallel-group Study to Assess the Bioequivalence of the Intravenous Formulation of Guselkumab Using Prefilled Syringes Assembled in an UltraSafe Plus Passive Needle Guard and Intravenous Formulation of Guselkumab Using Final Vialed Product in Healthy Participants

Next Previous
Trial Profile

An Open-label, Randomized, Parallel-group Study to Assess the Bioequivalence of the Intravenous Formulation of Guselkumab Using Prefilled Syringes Assembled in an UltraSafe Plus Passive Needle Guard and Intravenous Formulation of Guselkumab Using Final Vialed Product in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Crohn's disease; Erythrodermic psoriasis; Familial adenomatous polyposis; Hidradenitis suppurativa; Lupus nephritis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development

Most Recent Events

  • 25 Aug 2021 Status changed from recruiting to completed.
  • 24 Dec 2020 Status changed from not yet recruiting to recruiting.
  • 24 Nov 2020 Planned initiation date changed from 3 Nov 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top